Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition

Circulation

Volumn 103, Issue 11, 2001, Pages 1488-1491

  Osende, Julio I ^a,b   Fuster, Valentin ^a,b   Lev, Eli I ^a,b   Shimbo, Daichi ^a,b   Rauch, Ursula ^a,b   Marmur, Jonathan D ^a,b   Richard, Merwin ^a,b   Varon, David ^a,b   Badimon, Juan Jose ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Drugs; Platelets; Tests

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN;

ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; BOLUS INJECTION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BLOCKING; REFERENCE VALUE; SHEAR STRESS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 0035916935     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.11.1488     Document Type: Article

References (11)

1. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
2. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development
3. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: Fact or fancy?
4. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
5. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: Role of platelet activation, fibrinogen, and yon Willebrand factor
6. Rapid platelet-function assay: An automated and quantitative cartridge-based method
7. Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: Discriminating abciximab and small molecular weight antagonists
8. A revised model of platelet aggregation
9. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
10. Monitoring platelet GP IIb/IIIa antagonist therapy
11. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty